Changes in Levels of Biomarkers Associated with Adipocyte Function and Insulin and Glucagon Kinetics During Treatment with Dapagliflozin Among Obese Type 2 Diabetes Mellitus Patients

[1]  S. Ghose.  Glycemic Targets , 2018, TAJ: Journal of Teachers Association.

[2]  I. Hirsch,et al.  Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium–Glucose Cotransporter 2 Inhibition , 2015, Diabetes Care.

[3]  F. Pattou,et al.  Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion , 2015, Nature Medicine.

[4]  F. Gao,et al.  A reduction in both visceral and subcutaneous fats contributes to increased adiponectin by lifestyle intervention in the Diabetes Prevention Program , 2015, Acta Diabetologica.

[5]  A. Kiyosue,et al.  Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise , 2014, Diabetes, obesity & metabolism.

[6]  H. Maegawa,et al.  Dapagliflozin as Monotherapy or Combination Therapy in Japanese Patients with Type 2 Diabetes: an Open-Label Study , 2014, Diabetes Therapy.

[7]  M. Vitolins,et al.  Effects of a community-based weight loss intervention on adipose tissue circulating factors. , 2014, Diabetes & metabolic syndrome.

[8]  R. DeFronzo,et al.  Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. , 2014, The Journal of clinical investigation.

[9]  T. Heise,et al.  Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. , 2014, The Journal of clinical investigation.

[10]  F. Ashcroft,et al.  Role of KATP Channels in Glucose-Regulated Glucagon Secretion and Impaired Counterregulation in Type 2 Diabetes , 2013, Cell metabolism.

[11]  Kira B. Harris,et al.  The Clinical Efficacy and Safety of Sodium Glucose Cotransporter‐2 Inhibitors in Adults with Type 2 Diabetes Mellitus , 2013, Pharmacotherapy.

[12]  A. Barnett.  Impact of Sodium Glucose Cotransporter 2 Inhibitors on Weight in Patients With Type 2 Diabetes Mellitus , 2013, Postgraduate medicine.

[13]  N. Inagaki,et al.  Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study , 2013, Diabetes, obesity & metabolism.

[14]  Eric Verdin,et al.  Suppression of Oxidative Stress by β-Hydroxybutyrate, an Endogenous Histone Deacetylase Inhibitor , 2013, Science.

[15]  J. Kullberg,et al.  Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. , 2012, The Journal of clinical endocrinology and metabolism.

[16]  E. Chao.  A paradigm shift in diabetes therapy--dapagliflozin and other SGLT2 inhibitors. , 2011, Discovery medicine.

[17]  J. Gerich.  Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications , 2010, Diabetic medicine : a journal of the British Diabetic Association.

[18]  D. Petering,et al.  Enhanced expressions of sodium-glucose cotransporters in the kidneys of diabetic Zucker rats. , 2009, Diabetes research and clinical practice.

[19]  D. Panagiotakos,et al.  Genes, diet and type 2 diabetes mellitus: a review. , 2007, The review of diabetic studies : RDS.

[20]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[21]  M. Stumvoll,et al.  Renal gluconeogenesis: its importance in human glucose homeostasis. , 2001, Diabetes care.

[22]  R. Holman,et al.  Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study , 2000, BMJ : British Medical Journal.